The Cancer Letter

Inside information on cancer research and drug development

In Brief

Christoph Zielinski named editor-in-chief of ESMO Open

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

CHRISTOPH ZIELINSKI was named editor-in-chief of ESMO Open, a new open-access, peer-reviewed online journal published by the European Society of Medical Oncology.

Zielinski, 63, is director of the Clinical Division of Oncology and Chairman of the Department of Medicine I and the Comprehensive Cancer Centre at the Medical University in Vienna.

He has been president of the Central European Cooperative Oncology Group since 1999 and member of the ESMO executive board since 2014.

Zielinski’s research focuses on clinical trials in breast, lung cancer, personalized medicine and immuno-oncology. He has published more than 600 papers.

ESMO Open will operate a fast submission and review process with continuous publication online to ensure that timely, up-to-date research is available worldwide and adheres to a rigorous and transparent peer-review process.

The first articles will be published in January 2016.

Table of Contents

YOU MAY BE INTERESTED IN

AACR progress report highlights AI’s role in research and clinical care
Obstacles to progress include systemic disparities and dwindling appropriations

Artificial intelligence is starting to transform life sciences by accelerating drug discovery and development, optimizing clinical trials, and creating personalized treatments for cancer patients, speakers said at the Sept. 18 unveiling of the American Association for Cancer Research 2024 Cancer Progress Report. 
By McKenzie Prillaman
Table of Contents

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.
COMPLETE OUR SURVEY

Login

Site license subscribers:
Log in with your IP | Register a sponsored account